SOUTH SAN FRANCISCO, Calif., April 7, 2010 (GLOBE NEWSWIRE) -- OXiGENE, Inc.
(Nasdaq:OXGN), a clinical-stage biopharmaceutical company developing novel
therapeutics to treat cancer and eye diseases, today announced that it has
received a letter from NASDAQ Global Market exchange confirming that, with the
appointment of Tamar Howson to the Company's audit committee, as detailed in
the Company's Form 8-K filed on April 5, 2010, NASDAQ staff has determined that
the Company complies with Listing Rule 5605(c)(2) requiring the Company to have
at least three independent directors on its audit committee for continued
listing on the NASDAQ Global Market, and this matter is now closed.
About OXiGENE
OXiGENE is a clinical-stage biopharmaceutical company developing novel
therapeutics to treat cancer and eye diseases. The Company's major focus is
developing vascular disrupting agents (VDAs) that selectively disrupt abnormal
blood vessels associated with solid tumor progression and visual impairment.
OXiGENE is dedicated to leveraging its intellectual property and therapeutic
development expertise to bring life-extending and life-enhancing medicines to
patients.
The OXiGENE, Inc. logo is available at
http://www.globenewswire.com/newsroom/prs/?pkgid=4969
CONTACT: OXiGENE, Inc.
Investor and Media Contact:
Michelle Edwards, Investor Relations
650-635-7006
medwards@oxigene.com
OXiGENE Regains Compliance With NASDAQ Listing Requirements
| Source: Oxigene, Inc.
Attachments
